ISO 10993-1 2026: A Guide to Risk-Based Biocompatibility Testing

# ISO 10993-1: A Guide to Risk-Based Biocompatibility Evaluation The approach to establishing medical device safety is undergoing a significant evolution. Driven by updates to international standards like ISO 10993-1 and reinforced by regulatory bodies including the FDA and EU Notified Bodies, the industry is moving away from a historical, checklist-driven testing model. Instead, the focus is now on a comprehensive, risk-based biological evaluation process. This modern framework prioritizes a deep understanding of device materials and manufacturing processes, using chemical characterization and toxicological risk assessment to build a robust scientific rationale for safety, often reducing the need for traditional animal testing. This shift requires manufacturers to think like investigators, not just test requesters. The core question is no longer "Which tests from the matrix do we need to run?" but rather "What are the potential biological risks of our device, and what evidence do we need to collect to demonstrate an acceptable level of safety?" This process involves a meticulous evaluation documented in a Biological Evaluation Plan (BEP) and a final Biological Evaluation Report (BER), which together tell the complete safety story of the device. ## Key Points * **Risk-Based, Not Checklist-Driven:** The modern approach, guided by ISO 10993-1, emphasizes a holistic biological risk assessment. Simply completing every test in the matrix for a given category is no longer the standard; instead, each test must be justified. * **Chemical Characterization as the Foundation:** In-depth chemical analysis, particularly extractables and leachables (E&L) testing, is the starting point for understanding material-mediated risks. It identifies what chemical substances could potentially be released from a device. * **TRA Justifies Testing Reductions:** A robust Toxicological Risk Assessment (TRA) uses E&L data to evaluate the potential harm from identified chemicals. If the TRA demonstrates that exposure levels are well below safe limits, it can provide a powerful justification for forgoing certain biological tests. * **Manufacturing Processes Are Critical:** The biological evaluation must consider the final, finished device. Manufacturing processes like sterilization, cleaning, machining, and polishing can alter material surfaces, introduce contaminants, or leave residues that pose new biological risks. * **Documentation is Paramount:** The entire risk-based evaluation must be prospectively documented in a Biological Evaluation Plan (BEP) before testing begins and summarized cohesively in a final Biological Evaluation Report (BER) for the regulatory submission. * **Leverage Existing Data with Justification:** Using data from legacy devices or predicate materials is possible but requires a rigorous scientific rationale. This includes a gap analysis that compares materials, manufacturing processes, sterilization methods, and suppliers to prove equivalence. ## The Paradigm Shift: From Biocompatibility Testing to Biological Evaluation Historically, biocompatibility was often viewed as a set of standard biological tests (e.g., cytotoxicity, sensitization, irritation) chosen from a matrix in ISO 10993-1 based on the device's contact type and duration. The modern "biological evaluation" is a much broader, information-gathering process. **Biocompatibility Testing** is an *activity*—the execution of a specific biological or chemical test. **Biological Evaluation** is a *process*—a risk management framework used to assess the overall biological safety of a device. It uses information from various sources, including: * Material composition and characterization * Manufacturing process review * Data from literature and previously cleared devices * Chemical characterization (E&L) testing * Toxicological risk assessments * *And, where necessary,* biological testing This risk-based approach aligns with the "3Rs" principle—to Replace, Reduce, and Refine the use of animal testing wherever scientifically justifiable. ## Step 1: The Biological Evaluation Plan (BEP) The BEP is the strategic roadmap for the entire biological evaluation. It is a living document created *before* any new testing is initiated. Its purpose is to demonstrate to regulators that a thoughtful, risk-based plan is in place. ### Critical Components of a BEP: 1. **Device Description:** A detailed overview of the device, its intended use, the patient population, and the nature and duration of patient contact. This sets the context for all subsequent risk analysis. 2. **Material Characterization:** A complete list of all materials in the device that have direct or indirect patient contact, including colorants, additives, and processing aids. 3. **Manufacturing Process Review:** An assessment of how processes like machining, molding, cleaning, and sterilization could impact the final device's biocompatibility by leaving residues or changing the material surface. 4. **Categorization per ISO 10993-1:** The device is categorized based on its contact type (e.g., surface, implant) and duration (e.g., limited, prolonged, permanent), which informs the potential biological endpoints of concern. 5. **Initial Biological Risk Assessment:** Based on the information above, this section identifies potential biological risks. For example, an implant material may pose risks related to genotoxicity or chronic toxicity, while a surface-contacting adhesive may pose risks of sensitization or irritation. 6. **Review of Existing Data:** A thorough search and summary of available data on the device materials, including literature, supplier data (e.g., Master Files), clinical history, and information from similar predicate devices. 7. **Proposed Evaluation Strategy & Gap Analysis:** This is the core of the BEP. It outlines the plan to address the risks identified. It explicitly states which endpoints will be addressed by existing data, which will be addressed by chemical characterization and a TRA, and which require new biological testing. Crucially, it includes a justification for every decision, especially for forgoing tests listed in the ISO 10993-1 matrix. ## Step 2: Chemical Characterization and the Toxicological Risk Assessment (TRA) For many devices, especially those with prolonged or permanent patient contact, chemical characterization is the cornerstone of the biological evaluation. This data feeds directly into the TRA, which is the key to justifying a reduction in biological testing. ### The Role of Extractables & Leachables (E&L) Testing E&L testing is designed to identify and quantify the chemical substances that can migrate from a device under clinical use conditions. * **Extractables:** Compounds removed from the device using exaggerated conditions (e.g., aggressive solvents, high temperatures) to create a worst-case profile of what *could* be released. * **Leachables:** Compounds that migrate from the device under normal clinical conditions. The goal of the E&L study is to generate a comprehensive list of all potential chemicals and their concentrations. This requires sophisticated analytical chemistry techniques and must be planned carefully to ensure the extraction methods are scientifically sound and relevant to the device's intended use. ### From Data to Risk: Conducting the TRA Once the E&L data is available, a qualified toxicologist performs a TRA to determine if any of the identified chemicals pose a safety risk. The process generally follows these steps: 1. **Hazard Identification:** Each chemical compound from the E&L report is identified. 2. **Dose-Response Assessment:** The toxicologist researches toxicological databases and scientific literature to find the safe exposure limit for each compound, often expressed as a Tolerable Intake (TI) or Permissible Daily Exposure (PDE). If no data exists for a specific chemical, toxicological principles like the Threshold of Toxicological Concern (TTC) may be used. 3. **Exposure Assessment:** The maximum amount of each chemical a patient could be exposed to from the device is calculated. This is a worst-case calculation based on the E&L results and the clinical use of the device. 4. **Risk Characterization:** The toxicologist compares the calculated patient exposure to the safe limit to determine a **Margin of Safety (MOS)**. * **MOS = Tolerable Intake (TI) / Patient Exposure Dose** * A MOS greater than or equal to 1 generally indicates that the risk is acceptable. If the MOS is less than 1, the risk is potentially unacceptable, and further evaluation or biological testing may be required for that specific toxicological endpoint (e.g., genotoxicity, carcinogenicity). A well-executed TRA can provide sufficient evidence to conclude that risks for endpoints like systemic toxicity, genotoxicity, and carcinogenicity are negligible, thereby justifying the omission of the corresponding long-term animal tests. ## Step 3: The Biological Evaluation Report (BER) The BER is the final deliverable that summarizes the entire biological evaluation process. It ties together the plan from the BEP, all the data collected, and the final conclusions on safety. It must present a clear, traceable narrative for regulatory reviewers. ### Structuring a Defensible BER: * **Executive Summary:** A high-level overview of the evaluation and the final safety conclusion. * **Introduction and Scope:** Restates the device description, intended use, and the scope of the evaluation as defined in the BEP. * **Summary of Inputs:** Details on all materials, manufacturing processes, and existing data reviewed. * **Summary of Risk Assessment:** Presents the initial risk assessment and the evaluation plan for each endpoint. * **Summary of Test Results:** A clear presentation of all data gathered, including chemical characterization reports, TRA reports, and any biological test reports. * **Evaluation and Conclusions:** This section synthesizes all the information. For each relevant biological endpoint, it explains how the risk was evaluated (e.g., via TRA, biological test, or literature) and presents the conclusion. * **Overall Conclusion:** A final, unambiguous statement that the medical device is biologically safe and suitable for its intended use. ### Common Gaps That Trigger Regulatory Scrutiny: * **Insufficient Justification:** Simply stating a test was "not performed" is a major red flag. A detailed scientific rationale referencing the TRA, material history, or other data is required. * **Incomplete Chemical Characterization:** The E&L study must be comprehensive. Missing a class of compounds (e.g., focusing only on organics and ignoring inorganic elements) can lead to questions. * **Unqualified TRA:** A TRA must be conducted by a qualified toxicologist with documented experience. An assessment lacking depth or proper sourcing of toxicological data will be rejected. * **Ignoring Manufacturing:** Failure to address potential contaminants from manufacturing aids (e.g., cleaning agents, mold release agents) or residues from sterilization (e.g., ethylene oxide) is a frequent gap. * **Testing the Wrong Article:** The evaluation must be conducted on the final, finished device in its sterile packaging. Testing raw materials or non-sterilized components is generally insufficient. ## Strategic Considerations and the Role of Q-Submission For devices with novel materials, a complex manufacturing process, or for which a manufacturer intends to rely heavily on a TRA to justify omitting multiple biological tests, engaging with regulators early is a crucial de-risking strategy. The FDA's Q-Submission program allows manufacturers to present their proposed BEP and evaluation strategy to the agency for feedback *before* executing the plan. This pre-submission meeting can provide clarity on whether the FDA agrees with the proposed rationale for omitting tests, the design of the E&L study, or the overall approach. Gaining this alignment upfront can prevent significant delays and additional testing requests during the final review of the marketing submission. ## Key FDA References When preparing a biological evaluation, sponsors should refer to the latest official documents available on the FDA website. Key references often include: * FDA's Guidance on the Use of International Standard ISO 10993-1, 'Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process'. * Relevant sections of 21 CFR concerning Quality System Regulation and Good Manufacturing Practices, which govern process validation and control. * FDA's Q-Submission Program guidance for information on obtaining early feedback on testing strategies. ## Finding and Comparing Biocompatibility Testing Services Providers Choosing the right partner for biocompatibility evaluation is critical to success. A qualified provider is more than just a testing lab; they are a strategic partner who understands the risk-based approach. When evaluating potential providers, manufacturers should look for: * **ISO/IEC 17025 Accreditation:** This is a baseline requirement for quality and competence in testing laboratories. * **Integrated Expertise:** The ideal partner has in-house expertise across analytical chemistry (for E&L), toxicology (for TRA), and biological testing. This ensures a seamless and coherent evaluation process. * **Regulatory Experience:** Look for providers with a proven track record of successful submissions to the FDA and EU Notified Bodies. Ask about their experience defending risk-based justifications. * **Strategic Guidance:** A good partner will help develop the BEP, design an efficient E&L study, and structure a defensible BER. They should act as an extension of your regulatory team. Comparing providers involves more than just price. Inquire about their approach to risk-based evaluation, ask for redacted sample reports, and discuss their specific experience with your device type. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. *** This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*